Igencia (Burlingame, CA) a development-stage biopharmaceutical company focused on the discovery of tumor antigens and in vivo antibody screen platforms for various oncologic indications, closed a $24M Series B financing. Participants include The Column Group, OrbiMed and 5AM Ventures.